Exon

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

Retrieved on: 
Tuesday, September 7, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced fifteen recipients of Route 79, The Duchenne Scholarship Program.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced fifteen recipients of Route 79, The Duchenne Scholarship Program.
  • Recipients of this scholarship were chosen by an independent selection committee composed of Duchenne community members, who consider each applicants community involvement and a personal essay.
  • On behalf of Sarepta and the selection committee it is my pleasure to announce the 2021 recipients of Route 79, The Duchenne Scholarship Program and congratulate them on this achievement.
  • Route 79, TheDuchenne Scholarship Program is designed to help students diagnosed with Duchenne muscular dystrophy (Duchenne) pursue their post-high school educational goals.

Moore Kuehn Encourages VEI, IEC, XONE, and ASAX Investors to Contact Law Firm

Retrieved on: 
Tuesday, August 31, 2021
Telephone, Creation Technologies, Electronics, Desktop Metal, Chesapeake Energy, Wall Street, Fraud, Google, PLLC, Board, Astrea, IEC Electronics, Exon, Security (finance), Bank

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
    Vine Energy has agreed to merge with Chesapeake Energy.
  • Under the proposed transaction, Vine Energy shareholders will receive 0.2486 shares of Chesapeake Energy per share and $1.20 in cash per share.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update

Retrieved on: 
Thursday, August 12, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, CRL, Mutation, Regulation of tobacco by the U.S. Food and Drug Administration, HER2, Annual general meeting, U.S. Securities and Exchange Commission, Spectrum Pharmaceuticals, CEO, SPPI, American Society of Clinical Oncology, BLA, 8-K, EGFR, Food, Private Securities Litigation Reform Act, Exon, NSCLC, Total, Continuous operation, SEC, Research, NDA, FDA, Webcast, Annual report, Security (finance), Patient, CNS, Medication, Nasdaq, Safety, Society, ORR, Cohort, ASCO, Fine chemical, Pharmaceutical industry, Animal, Reinsurance, Spectrum Pharmaceuticals, Inc., ZENITH20, SPECTRUM PHARMACEUTICALS, INC., ZENITH20

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended June 30, 2021 and provided a corporate update.
  • Momentum continues to build with poziotinib and the submission of the NDA later this year is our top corporate priority, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Agilent Announces New SureSelect Human All Exon V8

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Technology, Genetics, Software, Biotechnology, Branches of biology, Biology, DNA, Molecular biology, Genomics, Human genetics, Wellcome Trust, Exome sequencing, Exome, Human genome, Exon, GENCODE

Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE.
  • The new design is available in three options routine exome sequencing (Exome v8), clinical research sequencing (v8 Clinical Plus), and translational research (v8 UTR Plus) allowing for content flexibility to meet our customers needs.
  • Powered by machine learning-based probe design and an improved probe-printing process, the SureSelect Human All Exon V8 spans a 35.1 Mb target region of the human genome, with an efficient end-to-end design size of only 41.6 Mb.
  • "The SureSelect Human All Exon V8 provides best-in-class enrichment performance and sequencing efficiency, and it shows our commitment to exceed customer expectations and continue our legacy as the benchmark exome to the genomics community."

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Retrieved on: 
Monday, May 3, 2021
Nucleic acids, Muscular dystrophy, Branches of biology, Dystrophin, Exon skipping, Exon, Drisapersen

Exon-skipping and dystrophin production in the 30 mg/kg cohort were also consistently higher than the 20 mg/kg cohort of MOMENTUM.

Key Points: 
  • Exon-skipping and dystrophin production in the 30 mg/kg cohort were also consistently higher than the 20 mg/kg cohort of MOMENTUM.
  • SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping.
  • Around 13% of DMD patients have mutations which make them amenable to skipping exon 51.
  • For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta.

Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

Retrieved on: 
Tuesday, August 25, 2020
Branches of biology, Muscular dystrophy, Biology, Nucleic acids, Morpholino, Duchenne muscular dystrophy, Exon skipping, Dystrophin, Exon, Drisapersen

Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the dystrophin gene.

Key Points: 
  • Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the dystrophin gene.
  • If it is approved, casimersen, our third exon-skipping medicine in our PMO RNA-based platform, will offer treatment to the 8% of Duchenne patients who are amenable to exon 45 skipping.
  • Casimersen uses Sareptas proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the Duchenne gene.
  • Casimersen is designed to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or skipping, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping.

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

Retrieved on: 
Friday, June 26, 2020
Branches of biology, Muscular dystrophy, Biology, Nucleic acids, Morpholino, Duchenne muscular dystrophy, Dystrophin, Exon skipping, Eteplirsen, Exon

Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.

Key Points: 
  • Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
  • If the casimersen NDA is accepted and granted accelerated approval, the completed ESSENCE study will serve as a post-marketing confirmatory study.
  • Casimersen uses Sareptas proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
  • Casimersen is designed to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or skipping, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping.

Global Exome Sequencing Market Report with Profiles of 10X Genomics, Agilent Technologies and Qiagen N.V.

Retrieved on: 
Monday, January 20, 2020
Branches of biology, Biology, Molecular biology, Genomics, Genetic mapping, DNA sequencing, DNA, Exome sequencing, Exome, Sequencing, Human genome, Exon

The "Exome Sequencing Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exome Sequencing Market" report has been added to ResearchAndMarkets.com's offering.
  • Exome Sequencing is a widely used NGS technique that sequences all the exons in a genome.
  • Rather than sequencing the entire human genome, only pieces of an individual's DNA that provide instructions for making proteins are sequenced.
  • The Exome Sequencing Market report provides the following data:
    Exome Sequencing Market by Region, 2019 (%; US, Europe, ROW)

Global Exome Sequencing Market to 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 2, 2020
Biotechnology, Genetics, Health, Branches of biology, Biology, Molecular biology, Biochemistry, DNA sequencing, DNA, Exome sequencing, Exome, Sequencing, Exon, Whole genome sequencing, DNA sequencer

The "Exome Sequencing Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exome Sequencing Market" report has been added to ResearchAndMarkets.com's offering.
  • The increasing popularity of next-generation systems has fueled systems and sequencers, but the cost of sequencing - despite price declines - has led to demands for more efficient methods.
  • Exome Sequencing is a widely used NGS technique that sequences all the exons in a genome.
  • The Exome Sequencing Market report provides the following data:
    Exome Sequencing Market by Region, 2019 (%; US, Europe, ROW)